RecruitingNot Applicable

Impact of Capillary Leak and Hypoalbuminemia on PK/PD of Anidulafungin and Caspofungin in Critically Ill Patients

Belgium60 participantsStarted 2012-09-21

Plain-language summary

This prospective study will explore the pharmacokinetic exposure and pharmacodynamics of the echinocandins (caspofungin or anidulafungin) in critically ill patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Treatment with anidulafungin or caspofungin * Admitted to an ICU ward Exclusion Criteria: * \< 18 years * DNR 2 or 3

What they're measuring

Area under the curve (AUC)

Timeframe: July 2020

Half-life (T1/2)

Timeframe: July 2020

Volume of distribution (Vd)

Timeframe: July 2020

Clearance (CL)

Timeframe: July 2020

Maximum plasma concentration

Timeframe: July 2020

Minimum plasma concentration

Timeframe: July 2020

Average plasma concentration

Timeframe: July 2020

Trial details

NCT IDNCT04045366

SponsorUniversitaire Ziekenhuizen KU Leuven

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-07-01

Contact for this trial

Isabel Spriet, PharmD, PhD

+32 16 34 30 80 isabel.spriet@uzleuven.be

View on ClinicalTrials.gov More Critically Ill Patients trials